Dimerix (ASX:DXB) is the kind of clinical-stage biotech that draws attention precisely because so much rides on a single program. The company's lead asset, DMX-200, is in a global Phase 3 trial, ACTION3, for focal segmental glomerulosclerosis (FSGS), a rare and serious kidney disease with no approved targeted therapy. Around that one drug, Dimerix has assembled a string of regional licensing deals that have transformed its Balance Sheet and lowered the stakes of a binary outcome, without removing them entirely.

That combination, a high-value late-stage trial plus a growing web of partnerships, is why Dimerix remains one of the most closely followed names on the ASX healthcare board.

The Everest deal and a licensing web

The most recent major catalyst came in June 2026, when Dimerix exclusively licensed DMX-200 rights for FSGS across Greater China, South Korea and Southeast Asia to Everest Medicines. The agreement carries a USD 10 million upfront payment (about AUD 14.1 million), up to USD 330 million in development, regulatory and commercial milestones, and tiered royalties of 10% to 15% on net sales, for total potential value of roughly AUD 481 million.

Dimerix described the Everest agreement as its fifth licensing deal for DMX-200. Across those partnerships, the company has said it is eligible for aggregate upfront and milestone payments of approximately AUD 1.9 billion, plus royalties, with partners taking on commercialisation in their territories while Dimerix continues funding the ACTION3 trial. That deal-making has been the practical engine behind the story, converting a single-asset biotech into a partnered franchise.

Where the ACTION3 trial stands

The science is the ultimate arbiter. As of an April 2026 update, a blinded assessment confirmed ACTION3 remained appropriately powered, at greater than 90%, to detect a treatment effect on its proteinuria primary endpoint. The adult cohort of 333 patients is fully recruited, while a separate paediatric cohort for ages 12 to 17 continued enrolling.

Importantly, Dimerix has signalled it intends to run the study through to completion at the proteinuria endpoint, with the last patient expected to receive their final dose around March 2028. An earlier futility analysis, passed in March 2024, showed the drug performing better than placebo, and the independent data monitoring committee has conducted multiple reviews without flagging safety concerns. These are encouraging process milestones, but they are not efficacy results; the pivotal readout is what will ultimately determine the outcome.

Why it matters, and the risks

For investors, the licensing income and non-dilutive milestones have materially de-risked the funding side of the equation, allowing Dimerix to progress its trial without the constant Equity raisings that plague many small biotechs. Success in FSGS would open a rare-disease market with significant unmet need.

The risks are stark and typical of the sector. Phase 3 trials can Fail even after positive interim signals; the primary endpoint must be met with statistical significance for the milestones and royalties to crystallise. The long timeline to a definitive dataset means years of waiting, regulatory approval is not guaranteed even with strong data, and much of the headline AUD 1.9 billion in potential payments is contingent on clinical and commercial milestones that may never be reached.

The balanced view

Dimerix pairs a genuinely high-stakes Phase 3 program with a portfolio of partnerships that has strengthened its finances and broadened its commercial reach. The near-term catalysts are trial progress, paediatric recruitment and any further licensing deals; the defining event remains the eventual ACTION3 efficacy result. It is a watchlist stock where conviction should rest on tolerance for binary clinical risk.